Norbert Ifrah

23.3k total citations · 2 hit papers
231 papers, 11.4k citations indexed

About

Norbert Ifrah is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Norbert Ifrah has authored 231 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Hematology, 69 papers in Public Health, Environmental and Occupational Health and 53 papers in Genetics. Recurrent topics in Norbert Ifrah's work include Acute Myeloid Leukemia Research (92 papers), Acute Lymphoblastic Leukemia research (68 papers) and Chronic Myeloid Leukemia Treatments (44 papers). Norbert Ifrah is often cited by papers focused on Acute Myeloid Leukemia Research (92 papers), Acute Lymphoblastic Leukemia research (68 papers) and Chronic Myeloid Leukemia Treatments (44 papers). Norbert Ifrah collaborates with scholars based in France, United States and Switzerland. Norbert Ifrah's co-authors include Michel Attal, Thierry Façon, Philippe Casassus, Catherine Payen, Jean‐François Rossi, Hervé Maisonneuve, Jean Roy, Hervé Dombret, Nöel Milpied and François Dreyfus and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Norbert Ifrah

221 papers receiving 11.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

1996 2.0k citations Norbert Ifrah, Catherine Payen et al. profile →
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

2014 479 citations Robert K. Hills, Sylvie Castaigné et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Norbert Ifrah

Since Specialization

Citations

This map shows the geographic impact of Norbert Ifrah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Ifrah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Ifrah more than expected).

Fields of papers citing papers by Norbert Ifrah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norbert Ifrah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Ifrah. The network helps show where Norbert Ifrah may publish in the future.

Co-authorship network of co-authors of Norbert Ifrah

This figure shows the co-authorship network connecting the top 25 collaborators of Norbert Ifrah. A scholar is included among the top collaborators of Norbert Ifrah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norbert Ifrah. Norbert Ifrah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML 2023 ·Blood ·(unknown), Nicolas Duployez, (unknown), Juliette Lambert, Maël Heiblig, Mathilde Hunault, Claude Gardin, Stéphane de Botton, Élise Fournier, Cécile Pautas, Christine Terré, Éric Delabesse, Norbert Ifrah, Arnaud Pigneux, (unknown), Christian Récher, Claude Preudhomme, Hervé Dombret, Raphaël Itzykson	0
2	Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup 2021 ·Science Translational Medicine ·Aurore Touzart, Anand Mayakonda, (unknown), Joschka Hey, Réka Tóth, Agata Cieślak, Guillaume P. Andrieu, Christine Tran Quang, (unknown), Jacques Ghysdael, Salvatore Spicuglia, Hervé Dombret, Norbert Ifrah, Elizabeth Macintyre, Pavlo Lutsik, Nicolas Boissel, Christoph Plass, Vahid Asnafi	23
3	Epigenetic Silencing Affects l -Asparaginase Sensitivity and Predicts Outcome in T-ALL 2019 ·Clinical Cancer Research ·Aurore Touzart, Étienne Lengliné, (unknown), Mohamed Belhocine, (unknown), Xavier Thomas, Salvatore Spicuglia, Denis Puthier, Françoise Pflumio, Thibaut Leguay, Carlos Graux, Yves Chalandon, Françoise Huguet, Stéphane Leprêtre, Norbert Ifrah, Hervé Dombret, Elizabeth Macintyre, Mathilde Hunault, Nicolas Boissel, Vahid Asnafi	28
4	Breast cancer screening: Impact on care pathways 2019 ·Cancer Medicine ·D. Lefeuvre, (unknown), Christine Le Bihan-Benjamin, Norbert Ifrah, Frédéric De Bels, Jérôme Viguier, Philippe‐Jean Bousquet	9
5	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia 2019 ·Blood Advances ·Marion Alcantara, Mathieu Simonin, Ludovic Lhermitte, Aurore Touzart, Marie-Émilie Dourthe, (unknown), Nathalie Grardel, Jean Michel Cayuela, Yves Chalandon, Carlos Graux, Hervé Dombret, Norbert Ifrah, Arnaud Petit, Elizabeth Macintyre, André Baruchel, Nicolas Boissel, Vahid Asnafi	14
6	Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission 2018 ·American Journal of Hematology ·Xavier Poiré, Myriam Labopin, Emmanuelle Polge, Didier Blaise, Patrice Chevallier, Johan Maertens, Éric Deconinck, Édouard Forcade, Alessandro Rambaldi, Gabriela M. Baerlocher, Tsila Zuckerman, Liisa Volin, Harry C. Schouten, Norbert Ifrah, Mohamad Mohty, Jordi Esteve, Arnon Nagler	13
7	Allogeneic stem cell transplantation in adult patients with acute myeloid leukemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European society of Blood and Marrow Transplantation (EBMT) 2016 ·Bone Marrow Transplantation ·Xavier Poiré, Myriam Labopin, Johan Maertens, Ibrahim Yakoub‐Agha, Didier Blaise, Norbert Ifrah, Gèrard Socié, (unknown), Nicolaas Schaap, (unknown), Nöel Milpied, Miguel Á. Sanz, Lucienne Michaux, Jordi Esteve, Mohamad Mohty, A Nagler	1
8	Correction: IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNγ 2014 ·PLoS ONE ·Etienne Foucher, (unknown), Laurence Preisser, Erwan Garo, Norbert Ifrah, Philippe Guardiola, Yves Delneste, Pascale Jeannin	1
9	Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup 2014 ·Leukemia & lymphoma ·Françoise Huguet, Thibaut Leguay, Emmanuel Raffoux, Philippe Rousselot, Norbert Vey, Arnaud Pigneux, Norbert Ifrah, Hervé Dombret	20
10	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials breakdown → 2014 ·The Lancet Oncology ·Robert K. Hills, Sylvie Castaigné, Frederick R. Appelbaum, Jacques Delaunay, Stephen H. Petersdorf, Megan Othus, Elihu H. Estey, Hervé Dombret, Sylvie Chevret, Norbert Ifrah, Jean‐Yves Cahn, Christian Récher, Lucy Chilton, Anthony V. Moorman, Alan K. Burnett	479
11	TET2 mutations in secondary acute myeloid leukemias: a French retrospective study 2011 ·Haematologica ·Olivier Kosmider, Éric Delabesse, Véronique Mansat‐De Mas, Pascale Cornillet‐Lefèbvre, Odile Blanchet, Alain Delmer, (unknown), Stéphane Raynaud, Didier Bouscary, F Viguié, C. Lacombe, Olivier Bernard, Norbert Ifrah, François Dreyfus, Michaëla Fontenay, (unknown)	31
12	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study 2011 ·Haematologica ·François Vergez, Alexa S. Green, Jérôme Tamburini, Jean‐Emmanuel Sarry, (unknown), Pascale Cornillet‐Lefèbvre, Mélanie Pannetier, Aymeric Neyret, Nicolas Chapuis, Norbert Ifrah, F. Dreyfus, Stéphane Manenti, Cécile Demur, Éric Delabesse, C. Lacombe, (unknown), Didier Bouscary, Christian Récher, Valérie Bardet	147
13	Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia 2010 ·Clinical Cancer Research ·Nicolas Chapuis, Jérôme Tamburini, Alexa S. Green, Christine Vignon, Valérie Bardet, Aymeric Neyret, Mélanie Pannetier, Lise Willems, Sophie Park, (unknown), Sauveur-Michel Maira, Norbert Ifrah, François Dreyfus, Olivier Hérault, Catherine Lacombe, Patrick Mayeux, Didier Bouscary	128
14	Addition of Lomustine to Idarubicin and Cytarabine Improves the Outcome of Elderly Patients With De Novo Acute Myeloid Leukemia: A Report From the GOELAMS 2010 ·Journal of Clinical Oncology ·Arnaud Pigneux, Jean‐Luc Harousseau, Francis Witz, (unknown), Marie C. Béné, Isabelle Luquet, Mathilde Hunault, Christian Récher, Bruno Lioure, Chantal Himberlin, Martine Escoffre‐Barbe, Christian Berthou, Séverine Lissandre, Nathalie Fegueux, Jean‐Yves Cahn, Éric Jourdan, François Dreyfus, Josy Reiffers, Nöel Milpied, Norbert Ifrah	26
15	Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody 2009 ·Haematologica ·Nicolas Chapuis, Jérôme Tamburini, Pascale Cornillet‐Lefèbvre, (unknown), Valérie Bardet, Lise Willems, Sophie Park, Alexa S. Green, Norbert Ifrah, François Dreyfus, Patrick Mayeux, C. Lacombe, Didier Bouscary	113
16	Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients 2007 ·Blood ·Jérôme Tamburini, Caroline Elie, Valérie Bardet, Nicolas Chapuis, Sophie Park, Philippe Broët, Pascale Cornillet‐Lefèbvre, Bruno Lioure, Valérie Ugo, Odile Blanchet, Norbert Ifrah, Francis Witz, François Dreyfus, Patrick Mayeux, Catherine Lacombe, Didier Bouscary	112
17	Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen–Identical Siblings Versus Human Leukocyte Antigen–Allelic–Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy 2006 ·Journal of Clinical Oncology ·Ibrahim Yakoub‐Agha, (unknown), Mathieu Kuentz, (unknown), Norbert Ifrah, Nöel Milpied, S Chehata, Hélène Espérou, Jean‐Paul Vernant, Mauricette Michallet, Agnès Buzyn, N Gratecos, J Cahn, Jean Henri Bourhis, Zina Chir, C Raffoux, Gèrard Socié, Jean Louis Golmard, Jean‐Pierre Jouet	189
18	Deregulated expression of theTAL1 gene by t(1;5)(p32;q31) in patient with T-cell acute lymphoblastic leukemia 1998 ·Genes Chromosomes and Cancer ·Sylvie François, Éric Delabesse, Laurence Baranger, (unknown), Charles Foussard, M Boasson, Odile Blanchet, Olivier Bernard, Elizabeth Macintyre, Norbert Ifrah	11
19	Histopathology of Bone Marrow after Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukaemia 1996 ·Pathology - Research and Practice ·(unknown), (unknown), Serge Guyétant, Sylvie François, Jean‐Paul Saint‐André, Norbert Ifrah	10
20	Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. 1990 ·Journal of Clinical Oncology ·Jean‐Marie Andrieu, Norbert Ifrah, Catherine Payen, Jean‐David Fermanian, Yvan Coscas, Georges Flandrin	108

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact